Evidence map›Paper›PMID 39390131›Full record

ArticleScientific reports2024

Intriguing hepatoprotective effects of sucrose on hepatocellular carcinoma pathogenesis.

Isaac Aguirre-Maldonado, Ema Elvira Herrera-López, Fernando López-Zenteno, Julio César Ramírez-Nava, Norma Arely López-Hernández, Jaime Arellanes-Robledo, Luis Del Pozo-Yauner, Rebeca García-Román, Hilda Montero, Alfonso Alexander-Aguilera and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Role of Dandelion (Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Isaac Aguirre-MaldonadoLaboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Alcaldía Tlalpan, 14610, Ciudad de México, Mexico.
Ema Elvira Herrera-LópezLaboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Alcaldía Tlalpan, 14610, Ciudad de México, Mexico.
Fernando López-ZentenoInstituto de Investigación en Ciencias de la Salud de la SEMAR, Ciudad de México, Mexico.
Julio César Ramírez-NavaInstituto de Investigación en Ciencias de la Salud de la SEMAR, Ciudad de México, Mexico.
Norma Arely López-HernándezLaboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Alcaldía Tlalpan, 14610, Ciudad de México, Mexico.
Jaime Arellanes-RobledoLaboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Alcaldía Tlalpan, 14610, Ciudad de México, Mexico.
Luis Del Pozo-YaunerDepartment of Pathology, College of Medicine, University of South Alabama, Alabama, USA.
Rebeca García-RománInstituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, Mexico.
Hilda MonteroInstituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, Mexico.
Alfonso Alexander-AguileraFacultad de Bioanálisis, Universidad Veracruzana, Veracruz, Mexico.
Juana Martha Noyola-DíazDepartamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, 07360, Ciudad de México, Mexico.
Javier CamachoDepartamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, 07360, Ciudad de México, Mexico.
Julio Isael Pérez-CarreónLaboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Alcaldía Tlalpan, 14610, Ciudad de México, Mexico. jiperez@inmegen.gob.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic liver disease is closely linked to dietary intake factors, such as high consumption of simple carbohydrates including sucrose. In this study, the influence of sucrose on the development of hepatocellular carcinoma (HCC), the most common primary liver malignancy, was explored. Using the hepatocarcinogen diethylnitrosamine (DEN) to induce HCC in the rat, we co-administered sucrose with DEN. The co-administration significantly modified body, liver and pancreas weight, as well as, serum fatty acids and triglycerides. DEN caused liver structural alteration, fibrosis, and tumor formation; surprisingly, co-administration with sucrose restored hepatic lipids, improved liver architecture, and reduced fibrosis and tumor development. Sucrose intake negatively regulated tumor markers and cell proliferation, and reduced the expression of genes associated with lipid metabolism and oxidative stress response. These findings highlight a hepatoprotective effect of sucrose during DEN-induced hepatocarcinogenesis, underlining an intriguing role of high sucrose consumption during HCC development and providing new insights as well as possible pathways of cellular protection under sucrose intake on hepatocarcinogenesis.

Indexed as

Carcinoma, HepatocellularDiethylnitrosamineLiver NeoplasmsSucroseAnimalsCell ProliferationLipid MetabolismLiverMaleOxidative StressProtective AgentsRatsDiethylnitrosamineProtective AgentsSucrose

Identifiers

PMID39390131
PMCPMC11467258

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.